Home › Funds › Atlas Venture Life Science Advisors, LLC › KLRA
Atlas Venture Life Science Advisors, LLC position in KLRA
KAILERA THERAPEUTICS INC · Health Care
Atlas Venture Life Science Advisors, LLC reported holding 5,171,282 shares of KLRA (KAILERA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$59.1M, representing 9.36% of its reported portfolio and ranking #4 among its reported holdings. Atlas Venture Life Science Advisors, LLC has disclosed KLRA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Atlas Venture Life Science Advisors, LLC's KLRA position evolved
Atlas Venture Life Science Advisors, LLC first disclosed a stake in KLRA in Q2 2026 at 5,171,282 shares (US$113.9M). Across 2 filings, Atlas Venture Life Science Advisors, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 5,171,282 shares valued at US$59.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 5.17M | $113.92M | New |
| Q3 2026 | 5.17M | $59.06M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KLRA and 13F data
KLRA (KAILERA THERAPEUTICS INC) is a Health Care company. 130 other funds we track also report a position in KLRA — the largest reported positions include BAIN CAPITAL INVESTORS LLC (US$578.4M), Bain Capital Life Sciences Investors, LLC (US$497.5M), RTW INVESTMENTS, LP (US$237.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KLRA
- BAIN CAPITAL INVESTORS LLC 26.26M sh · $578.41M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 22.58M sh · $497.51M · Q2 2026
- RTW INVESTMENTS, LP 10.78M sh · $237.41M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 2.46M sh · $54.09M · Q2 2026
- Siren, L.L.C. 2.21M sh · $25.29M · Q3 2026
- Farallon Capital Management 1.10M sh · $24.23M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 1.10M sh · $24.23M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.10M sh · $24.23M · Q2 2026
- Trails Edge Capital Partners, LP 984.79K sh · $21.69M · Q2 2026
- Cormorant Asset Management, LP 550.00K sh · $12.12M · Q2 2026
- Catalio Capital Management, LP 468.75K sh · $10.33M · Q2 2026
- a16z Capital Management, L.L.C. 140.00K sh · $3.08M · Q2 2026
More on Atlas Venture Life Science Advisors, LLC
FAQ
How long has Atlas Venture Life Science Advisors, LLC held KLRA?
Atlas Venture Life Science Advisors, LLC has disclosed KLRA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Atlas Venture Life Science Advisors, LLC's current position in KLRA?
As of Q3 2026, Atlas Venture Life Science Advisors, LLC holds 5.17M shares of KLRA (KAILERA THERAPEUTICS INC), valued at $59.06M, representing 9.36% of its reported portfolio and ranking #4.
Has Atlas Venture Life Science Advisors, LLC been buying or selling KLRA?
In the latest 13F filing (Q3 2026), Atlas Venture Life Science Advisors, LLC held unchanged its position in KLRA.
Which other funds hold KLRA?
Other major institutional holders of KLRA include BAIN CAPITAL INVESTORS LLC, Bain Capital Life Sciences Investors, LLC, RTW INVESTMENTS, LP, among 130 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.